{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:37:35Z","timestamp":1776872255991,"version":"3.51.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Hope RUN Special Fund of Cancer Foundation of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-invasive, especially the urine-based diagnosis of prostate cancer (PCa) remains challenging. Although prostate cancer antigen (PSA) is widely used in prostate cancer screening, the false positives may result in unnecessary invasive procedures. PSA elevated patients are triaged to further evaluation of free\/total PSA ratio (f\/t PSA), to find out potential clinically significant PCa before undergoing invasive procedures. Genomic instability, especially chromosomal copy number variations (CNVs) were proved much more tumor specific. Here we performed a prospective study to evaluate the diagnostic value of CNV via urine-exfoliated cell DNA analysis in PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 28 PSA elevated patients (\u2265\u20094\u00a0ng\/ml), including 16 PCa, 9 benign prostate hypertrophy (BPH) and 3 prostatic intraepithelial neoplasia (PIN). Fresh initial portion urine was collected after hospital admission. Urine exfoliated cell DNA was analyzed by low coverage Whole Genome Sequencing, followed by CNV genotyping by the prostate cancer chromosomal aneuploidy detector (ProCAD). CNVs were quantified in absolute z-score (|Z|). Serum free\/total PSA ratio (f\/t PSA) was reported altogether.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In patients with PCa, the most frequent CNV events were chr3q gain (n\u2009=\u20092), chr8q gain (n\u2009=\u20092), chr2q loss (n\u2009=\u20094), and chr18q loss (n\u2009=\u20093). CNVs were found in 81.2% (95% Confidence Interval (CI) 53.7\u201395.0%) PCa. No CNV was identified in BPH patients. A diagnosis model was established by incorporating all CNVs. At the optimal cutoff of |Z|\u2265\u20092.50, the model reached an AUC of 0.91 (95% CI 0.83\u20130.99), a sensitivity of 81.2% and a specificity of 100%. The CNV approach significantly outperformed f\/t PSA (AUC\u2009=\u20090.62,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.012). Further analyses showed that the CNV positive rate was significantly correlated with tumor grade. CNVs were found in 90.9% (95% CI 57.1\u201399.5%) high grade tumors and 60.0% (95% CI 17.0\u201392.7%) low grade tumors. No statistical significance was found for patient age, BMI, disease history and family history.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Urine exfoliated cells harbor enriched CNV features in PCa patients. Urine detection of CNV might be a biomarker for PCa diagnosis, especially in terms of the clinically significant high-grade tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-022-01253-5","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T04:17:23Z","timestamp":1651724243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study"],"prefix":"10.1186","volume":"15","author":[{"given":"Youyan","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaopeng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingang","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhendong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zejun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingli","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Shou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziliang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"issue":"2","key":"1253_CR1","first-page":"115","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1253_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1253_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/his.13712","volume":"74","author":"A Matoso","year":"2019","unstructured":"Matoso A, Epstein JI. Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. 2019;74(1):135\u201345.","journal-title":"Histopathology"},{"issue":"11","key":"1253_CR4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/archinte.164.11.1227","volume":"164","author":"RP Smith","year":"2004","unstructured":"Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Tochner Z, Wein AJ. Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med. 2004;164(11):1227\u201330.","journal-title":"Arch Intern Med"},{"issue":"13","key":"1253_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0901825","volume":"360","author":"TH Lee","year":"2009","unstructured":"Lee TH, Kantoff PW, McNaughton-Collins MF. Screening for prostate cancer. N Engl J Med. 2009;360(13): e18.","journal-title":"N Engl J Med"},{"issue":"7","key":"1253_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa1201637","volume":"367","author":"EA Heijnsdijk","year":"2012","unstructured":"Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Paez A, Moss SM, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367(7):595\u2013605.","journal-title":"N Engl J Med"},{"issue":"16","key":"1253_CR7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMms1914228","volume":"382","author":"HG Welch","year":"2020","unstructured":"Welch HG, Albertsen PC. Reconsidering prostate cancer mortality\u2014the future of PSA screening. N Engl J Med. 2020;382(16):1557\u201363.","journal-title":"N Engl J Med"},{"issue":"13","key":"1253_CR8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMsb1616281","volume":"376","author":"PF Pinsky","year":"2017","unstructured":"Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening\u2014a perspective on the current state of the evidence. N Engl J Med. 2017;376(13):1285\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"1253_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1569-9056(02)00053-2","volume":"1","author":"MB Gretzer","year":"2002","unstructured":"Gretzer MB. Partin AWJEUS: PSA levels and the probability of prostate cancer on biopsy. Eur Urol Suppl. 2002;1(6):21\u20137.","journal-title":"Eur Urol Suppl"},{"issue":"19","key":"1253_CR10","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1001\/jama.2017.4413","volume":"317","author":"K Bibbins-Domingo","year":"2017","unstructured":"Bibbins-Domingo K, Grossman DC, Curry SJ. The US preventive services task force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA. 2017;317(19):1949\u201350.","journal-title":"JAMA"},{"issue":"8","key":"1253_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1442-2042.2005.01167.x","volume":"12","author":"Y Nakano","year":"2010","unstructured":"Nakano Y, Okamura K, Takamura S, Okamoto N. Nagasaka TJIJoU: measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4\u201320 ng\/mL. Int J Urol. 2010;12(8):721\u20137.","journal-title":"Int J Urol"},{"issue":"13","key":"1253_CR12","doi-asserted-by":"publisher","first-page":"e0249","DOI":"10.1097\/MD.0000000000010249","volume":"97","author":"Y Huang","year":"2018","unstructured":"Huang Y, Li ZZ, Huang YL, Song HJ, Wang YJ. Value of free\/total prostate-specific antigen (f\/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng\/mL: a meta-analysis. Medicine (Baltimore). 2018;97(13):e0249.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1253_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/pcan.2009.31","volume":"13","author":"T Jamaspishvili","year":"2010","unstructured":"Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(1):12\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"1253_CR14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","volume":"174","author":"SF Bakhoum","year":"2018","unstructured":"Bakhoum SF, Cantley LC. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell. 2018;174(6):1347\u201360.","journal-title":"Cell"},{"issue":"7","key":"1253_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41576-019-0114-6","volume":"20","author":"S Turajlic","year":"2019","unstructured":"Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20(7):404\u201316.","journal-title":"Nat Rev Genet"},{"issue":"7283","key":"1253_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899\u2013905.","journal-title":"Nature"},{"issue":"21","key":"1253_CR17","doi-asserted-by":"publisher","first-page":"5646","DOI":"10.1158\/1078-0432.CCR-20-0401","volume":"26","author":"S Zeng","year":"2020","unstructured":"Zeng S, Ying Y, Xing N, Wang B, Qian Z, Zhou Z, Zhang Z, Xu W, Wang H, Dai L, et al. Noninvasive detection of urothelial carcinoma by cost-effective low-coverage whole-genome sequencing from urine-exfoliated cell DNA. Clin Cancer Res. 2020;26(21):5646\u201354.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"1253_CR18","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1002\/cam4.3142","volume":"9","author":"S Feng","year":"2020","unstructured":"Feng S, Ding Z, Wang J, Qian Z, Li S, Zhang C, Xin H, Liu S, Ding G, Hu M, et al. Investigation of plasma cell-free cancer genome chromosomal instability as a tool for targeted minimally invasive biomarkers for primary liver cancer diagnoses. Cancer Med. 2020;9(14):5075\u201385.","journal-title":"Cancer Med"},{"issue":"1","key":"1253_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10549-019-05375-w","volume":"178","author":"H Zhou","year":"2019","unstructured":"Zhou H, Wang XJ, Jiang X, Qian Z, Chen T, Hu Y, Chen ZH, Gao Y, Wang R, Ye WW, et al. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse. Breast Cancer Res Treat. 2019;178(1):63\u201373.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1253_CR20","doi-asserted-by":"publisher","first-page":"100908","DOI":"10.1016\/j.tranon.2020.100908","volume":"14","author":"X Wang","year":"2021","unstructured":"Wang X, Fu XH, Qian ZL, Zhao T, Duan AQ, Ruan X, Zhu B, Yin L, Zhang YJ, Yu WL. Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: a prospective cohort study. Transl Oncol. 2021;14(1):100908.","journal-title":"Transl Oncol"},{"issue":"4","key":"1253_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research N","year":"2015","unstructured":"Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011\u201325.","journal-title":"Cell"},{"issue":"3","key":"1253_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41391-020-0212-8","volume":"23","author":"X Wang","year":"2020","unstructured":"Wang X, Grasso CS, Jordahl KM, Kolb S, Nyame YA, Wright JL, Ostrander EA, Troyer DA, Lance R, Feng Z, et al. Copy number alterations are associated with metastatic-lethal progression in prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(3):494\u2013506.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"23","key":"1253_CR23","doi-asserted-by":"publisher","first-page":"11390","DOI":"10.1073\/pnas.1902645116","volume":"116","author":"KH Stopsack","year":"2019","unstructured":"Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci USA. 2019;116(23):11390\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"1253_CR24","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. Genome project data processing S: the sequence alignment\/map format and SAMtools. Bioinformatics. 2009;25(16):2078\u20139.","journal-title":"Bioinformatics"},{"key":"1253_CR25","unstructured":"Seshan VE, Olshen A. DNAcopy: DNA copy number data analysis. R package version 1530. 2017."},{"issue":"3","key":"1253_CR26","first-page":"1471","volume":"38","author":"J Guo","year":"2018","unstructured":"Guo J, Yang J, Zhang X, Feng X, Zhang H, Chen L, Johnson H, Persson JL, Xiao K. A panel of biomarkers for diagnosis of prostate cancer using urine samples. Anticancer Res. 2018;38(3):1471\u20137.","journal-title":"Anticancer Res"},{"issue":"5","key":"1253_CR27","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/cncr.20480","volume":"101","author":"J Hernandez","year":"2004","unstructured":"Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101(5):894\u2013904.","journal-title":"Cancer"},{"issue":"12","key":"1253_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/MLR.0b013e318269e096","volume":"50","author":"AA Kotwal","year":"2012","unstructured":"Kotwal AA, Schumm P, Mohile SG, Dale W. The influence of stress, depression, and anxiety on PSA screening rates in a nationally representative sample. Med Care. 2012;50(12):1037\u201344.","journal-title":"Med Care"},{"issue":"4","key":"1253_CR29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0090-4295(02)02427-5","volume":"61","author":"K Ito","year":"2003","unstructured":"Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free\/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng\/mL. Urology. 2003;61(4):760\u20134.","journal-title":"Urology"},{"issue":"17","key":"1253_CR30","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1080\/15384101.2015.1068482","volume":"14","author":"AY Kuznetsova","year":"2015","unstructured":"Kuznetsova AY, Seget K, Moeller GK, de Pagter MS, de Roos JA, Durrbaum M, Kuffer C, Muller S, Zaman GJ, Kloosterman WP, et al. Chromosomal instability, tolerance of mitotic errors and multidrug resistance are promoted by tetraploidization in human cells. Cell Cycle. 2015;14(17):2810\u201320.","journal-title":"Cell Cycle"},{"issue":"6","key":"1253_CR31","doi-asserted-by":"publisher","first-page":"a029611","DOI":"10.1101\/cshperspect.a029611","volume":"7","author":"SF Bakhoum","year":"2017","unstructured":"Bakhoum SF, Landau DA. Chromosomal instability as a driver of tumor heterogeneity and evolution. Cold Spring Harb Perspect Med. 2017;7(6):a029611.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"1253_CR32","first-page":"67","volume":"31","author":"PL Choyke","year":"2017","unstructured":"Choyke PL, Loeb S. Active surveillance of prostate cancer. Oncology (Williston Park). 2017;31(1):67\u201370.","journal-title":"Oncology (Williston Park)"},{"issue":"10","key":"1253_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127\u201333.","journal-title":"Nat Genet"},{"issue":"12","key":"1253_CR34","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/jmv.21312","volume":"80","author":"G Russo","year":"2008","unstructured":"Russo G, Anzivino E, Fioriti D, Mischitelli M, Bellizzi A, Giordano A, Autran-Gomez A, Di Monaco F, Di Silverio F, Sale P, et al. p53 gene mutational rate, Gleason score, and BK virus infection in prostate adenocarcinoma: Is there a correlation? J Med Virol. 2008;80(12):2100\u20137.","journal-title":"J Med Virol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-022-01253-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:40:48Z","timestamp":1776868848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12920-022-01253-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":34,"journal-issue":{"issue":"S2","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["1253"],"URL":"https:\/\/doi.org\/10.1186\/s12920-022-01253-5","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective study was approved by the Ethics Committee of National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (NO: 21\/096-2767). All participants provided written informed consent prior to entering the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}